Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash from Operations (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Cash from Operations for 7 consecutive years, with 126151000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 66.95% to 126151000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 348199000.0 through Dec 2025, up 58.4% year-over-year, with the annual reading at 348199000.0 for FY2025, 58.4% up from the prior year.
  • Cash from Operations hit 126151000.0 in Q4 2025 for Harmony Biosciences Holdings, up from 108734000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 126151000.0 in Q4 2025 to a low of 12530000.0 in Q1 2021.
  • Historically, Cash from Operations has averaged 51521500.0 across 5 years, with a median of 40046000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: soared 273.97% in 2021 and later fell 28.92% in 2022.
  • Year by year, Cash from Operations stood at 37533000.0 in 2021, then dropped by 28.92% to 26678000.0 in 2022, then soared by 187.37% to 76665000.0 in 2023, then decreased by 1.44% to 75562000.0 in 2024, then skyrocketed by 66.95% to 126151000.0 in 2025.
  • Business Quant data shows Cash from Operations for HRMY at 126151000.0 in Q4 2025, 108734000.0 in Q3 2025, and 79327000.0 in Q2 2025.